Source:http://linkedlifedata.com/resource/pubmed/id/12183664
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2002-8-16
|
pubmed:abstractText |
Secretin is a gastrointestinal peptide belonging to the vasoactive intestinal peptide (VIP)/glucagon/pituitary adenylate cyclase-activating polypeptide (PACAP) family recently suggested to have therapeutic effects in autism. A direct effect on brain would require secretin to cross the blood-brain barrier (BBB), an ability other members of the VIP/PACAP family have. Herein, we examined whether a secretin analog (SA) radioactively labeled with (131)I (I-SA) could cross the BBB of 4-week-old mice. We found I-SA was rapidly cleared from serum with fragments not precipitating with acid appearing in brain and serum. Levels of radioactivity were corrected to reflect only intact I-SA as estimated by acid precipitation. After i.v. injection, I-SA was taken up by brain at a modest rate of 0.9 to 1.5 microl/g-mm. Capillary depletion, brain perfusion, and high-performance liquid chromatography were used to confirm the passage of intact I-SA across the BBB. I-SA entered every brain region, with the highest uptake into the hypothalamus and cerebrospinal fluid (CSF). Unlabeled SA (10 microg/mouse) did not inhibit uptake by brain but did inhibit clearance from blood and uptake by the CSF, colon, kidney, and liver. The decreased clearance of I-SA from blood increased the percentage of the i.v. injected dose taken up per brain (%Inj/g) from about 0.118 to 0.295%Inj/g. In conclusion, SA crosses the vascular barrier by a nonsaturable process and the choroid plexus by a saturable process in amounts that for other members of its family produce central nervous system (CNS) effects. This passage provides a pathway through which peripherally administered SA could affect the CNS.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
302
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1062-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12183664-Algorithms,
pubmed-meshheading:12183664-Animals,
pubmed-meshheading:12183664-Blood-Brain Barrier,
pubmed-meshheading:12183664-Capillary Permeability,
pubmed-meshheading:12183664-Chromatography, High Pressure Liquid,
pubmed-meshheading:12183664-Injections, Intravenous,
pubmed-meshheading:12183664-Male,
pubmed-meshheading:12183664-Mice,
pubmed-meshheading:12183664-Mice, Inbred ICR,
pubmed-meshheading:12183664-Regression Analysis,
pubmed-meshheading:12183664-Secretin,
pubmed-meshheading:12183664-Solubility,
pubmed-meshheading:12183664-Solvents,
pubmed-meshheading:12183664-Tissue Distribution
|
pubmed:year |
2002
|
pubmed:articleTitle |
Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse.
|
pubmed:affiliation |
Geriatric Research, Education, and Clinical Center, St. Louis University School of Medicine, 915 N. Grand Boulevard, St. Louis, MO 63106, USA. bankswa@slu.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|